Survodutide
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
Boehringer Ingelheim · Phase 2 · Completed · Enrollment 387
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
- 0.6 mg BI 456906
- Placebo group
- 2.4 mg BI456906
- 3.6 mg BI 456906
- 4.8 mg BI 456906
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 0.6 mg BI 456906 | 60.7% | 33.9% | 12.5% | n/r |
| Placebo group | 25.9% | 11.1% | 5.6% | n/r |
| 2.4 mg BI456906 | 81% | 65.5% | 37.9% | n/r |
| 3.6 mg BI 456906 | 82% | 65.6% | 45.9% | n/r |
| 4.8 mg BI 456906 | 82.8% | 68.8% | 54.7% | n/r |
Not shown
Every selected arm is drawn.